Altimmune, Inc. (NASDAQ:ALT) Receives $18.80 Average Target Price from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $18.80.

A number of equities research analysts recently commented on the company. Evercore ISI raised Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. B. Riley reiterated a “buy” rating and issued a $20.00 target price on shares of Altimmune in a report on Monday, August 12th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Thursday, August 22nd.

Altimmune Price Performance

NASDAQ:ALT opened at $6.69 on Thursday. Altimmune has a one year low of $2.24 and a one year high of $14.84. The company has a market cap of $475.46 million, a PE ratio of -4.13 and a beta of 0.08. The firm has a 50-day moving average of $6.77 and a 200-day moving average of $6.89.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. The company had revenue of $0.01 million for the quarter. During the same period in the prior year, the company earned ($0.32) earnings per share. On average, equities research analysts expect that Altimmune will post -0.54 earnings per share for the current fiscal year.

Insider Activity

In other Altimmune news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the transaction, the director now directly owns 41,958 shares in the company, valued at $289,510.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.10% of the company’s stock.

Institutional Trading of Altimmune

Several hedge funds have recently made changes to their positions in ALT. Dimensional Fund Advisors LP raised its position in shares of Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares during the period. Knoll Capital Management LLC lifted its position in shares of Altimmune by 183.6% during the first quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock worth $5,774,000 after acquiring an additional 367,219 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Altimmune by 1,282.4% in the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock worth $4,785,000 after acquiring an additional 436,000 shares during the period. BBR Partners LLC grew its position in shares of Altimmune by 4.5% in the second quarter. BBR Partners LLC now owns 374,784 shares of the company’s stock valued at $2,492,000 after purchasing an additional 16,271 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Altimmune by 542.8% during the 2nd quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock valued at $1,693,000 after purchasing an additional 214,968 shares during the period. 78.05% of the stock is currently owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.